Using Estetrol and Drospirenone to Shrink Ovarian Endometriomas
Official title: Estetrol/Drospirenone to Reduce the Average Size of Endometriomas
Run by McGill University Health Centre/Research Institute of the McGill University Health Centre · NCT05837624 · Data updated 2026-11-12
This study is testing if a hormonal treatment called Estetrol and Drospirenone can help shrink painful ovarian cysts in women with endometriosis and improve their chances of getting pregnant.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 21 (estimated) |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | December 3, 2024 |
| Main results expected | July 2027 |
| Study ends | August 2027 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT05837624 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 18 and older with at least one ovarian endometrioma measuring 3 cm or larger who are seeking hormonal treatment.
✕Probably not a fit
Patients with allergies or contraindications to the study drug or those who have used certain hormones in the past three months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of Estetrol/Drospirenone in reducing the size of ovarian endometriomas, which are cysts associated with endometriosis that can cause pain and infertility. The study aims to provide a non-surgical medical management option for patients suffering from these cysts, particularly in light of reduced surgical access due to the COVID-19 pandemic. Participants will receive hormonal treatment to alleviate symptoms and potentially improve fertility outcomes. The trial will include women aged 18 and older with endometriomas of at least 3 cm seeking hormonal therapy.
Why it matters
Potential benefit: If successful, this treatment could provide a non-surgical option for women to manage endometriomas, alleviating pain and preserving fertility.
How similar studies have gone: Other studies have shown that medical management can effectively reduce endometrioma size, making this approach promising but not entirely novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Equal to or greater than 18 years old * Has at least one ovarian endometrioma, of at least 3 cm * Seeking a hormonal treatment for their endometrioma(s) Exclusion criteria: * Any allergy or contraindication to the study drug * Inability to provide informed consent * Any hormone use, from the following list, within last 3 months (excluding hormones used for ovarian stimulation for fertility treatments): Estrogen (agonist or antagonist), Progestogen (agonist or antagonist), Androgen (agonist or antagonist), GnRH (agonist or antagonist), Cabergoline
Where it's running
-
McGill University Health Center
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Andrew Zakhari, M.D. — McGill University Health Centre/Research Institute of the McGill University Health Centre
- Study coordinator: Andrew Zakhari, M.D.
- Email: andrew.zakhari@mcgill.ca
- Phone: 5142288889
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Depth of Argon Beam Coagulation in Ovarian Endometriomas
This study tests how deeply Argon Beam Coagulation affects ovarian tissue during laparoscopic surgery for ovarian endometriomas in women aged 18-40.
-
Selective removal of endometriotic lining from ovarian endometriomas using CUSA Clarity
This project will try the CUSA Clarity device on tissue from women with ovarian endometriomas to see if it removes endometriotic lining while preserving healthy ovarian tissue.
-
Surgical options to preserve ovaries when treating endometriomas
This trial will see if different surgical methods for treating endometriomas help women who want to get pregnant have higher pregnancy and birth rates and fewer complications.
-
Vaginal ultrasound-guided ethanol sclerotherapy versus laparoscopic cystectomy for ovarian endometriomas.
This study will test whether vaginal ultrasound-guided ethanol sclerotherapy works as well as laparoscopic cystectomy to treat ovarian endometriomas in symptomatic women aged 18–45.
-
Ethanol sclerotherapy for treating ovarian endometriomas
This study tests if a treatment using ultrasound-guided ethanol can help women with painful ovarian cysts shrink them and reduce their symptoms.
-
Alcohol sclerotherapy for pelvic pain and quality of life in ovarian endometrioma
This trial will try ultrasound-guided alcohol sclerotherapy to see if it reduces pelvic pain and improves quality of life in women aged 18–45 with ovarian endometriomas compared with expectant management.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.